Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Use of Recombinant hCG to Prevent Breast Cancer in BRCA1 and BRCA2 Carriers

NCT03495609 is registered in ClinicalTrials.gov with University Hospital, Ghent as lead sponsor.

NCT NCT03495609
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03495609 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Use of Recombinant hCG to Prevent Breast Cancer in BRCA1 and BRCA2 Carriers
Lead sponsor
University Hospital, Ghent
Phase
Phase 4
Overall status
Completed
Start date
February 17, 2016
Completion date
December 18, 2018
Enrollment
33 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brca1 mutation, brca2 mutation, hcg